Colombia vs Saudi Arabia: Prevalence rate of hypertension in women aged 30-79
Colombia
30.8
in 2019
Saudi Arabia
30.2
in 2019
Colombia rank
151st
Saudi Arabia rank
154th
Prevalence rate of hypertension in women aged 30-79 over time
- Colombia
- Saudi Arabia
How they compare
Colombia currently reports 30.8 against 30.2 in Saudi Arabia, a difference of 0.6.
The two have swapped places 1 time across 30 shared years of data; in 1990 it was Saudi Arabia ahead.
Colombia ranks 151st and Saudi Arabia ranks 154th of 195 countries.
Saudi Arabia has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Colombia | Saudi Arabia | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 29.64 | 34.32 | 4.68 | Saudi Arabia |
| 2000s | 30.98 | 33.93 | 2.95 | Saudi Arabia |
| 2010s | 31.19 | 31.65 | 0.46 | Saudi Arabia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence rate of hypertension in women aged 30-79, Colombia or Saudi Arabia?
- Colombia, at 30.8 against 30.2 in Saudi Arabia as of 2019.
- What is the difference in prevalence rate of hypertension in women aged 30-79 between Colombia and Saudi Arabia?
- 0.6, with Colombia ahead.
- How many years of comparable data are there for Colombia and Saudi Arabia?
- 30 years are reported by both, from 1990 to 2019.
- How do Colombia and Saudi Arabia rank globally for prevalence rate of hypertension in women aged 30-79?
- Colombia ranks 151st and Saudi Arabia ranks 154th of 195 countries.
- Where does this data come from?
- World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data, published as Prevalence rate of hypertension in women aged 30-79. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Estimated share of female population with hypertension, based on population representative surveys and statistical modeling. Hypertension is a risk factor for chronic complications, including cardiovascular disease, and premature death.